ArticleBreast cancer research : BCR2025
Differential prognostic significance of tumor size and node in invasive lobular carcinoma of breast.
Article in Breast cancer research : BCR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInvasive lobular carcinoma (ILC) is the second most common histological type of breast cancer. Despite its distinct clinical and pathological characteristics, ILC shares the same prognostic classification system and adjuvant treatment strategies as invasive ductal carcinoma (IDC).
methodsWe reviewed the data of the 16,365 IDC and ILC patients who were treated between 2005 and 2022 at Seoul National University Hospital (SNUH). Also, we conducted a parallel analysis using the data of 247,290 IDC and ILC treated between 2010 and 2015 from the surveillance, epidemiology, and end results (SEER) database.
resultsILC patients were older at diagnosis, had larger tumors, and ILC tumors were predominantly HR-positive/HER2-negative. ILC exhibited unique prognostic implications of anatomic features. Unlike in IDC, the tumor size and nodal status showed differential prognostic impact on survival in ILC. While there was no significant survival difference for different T stages in ILC patients, the prognostic impact of nodal involvement was more pronounced for ILC in the SNUH dataset. Similar survival implication of tumor size and nodal involvement was observed for the ILC cases in the SEER dataset.
conclusionIn ILC, tumor size may not be as strong a predictor of survival as in IDC, while advanced nodal involvement carries a particularly high risk for breast cancer-specific mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.